

# Randomised Controlled Trial Comparing Rituximab to Mycophenolate Mofetil in Children and Young Adults with Steroid-Dependent Idiopathic Nephrotic Syndrome



## Methods



Multicenter, open label,  
2 parallel arm study



Superiority controlled RCT



Aged 2 - 24 years



Steroid dependent idiopathic  
nephrotic syndrome



MMF  
1200 mg/m<sup>2</sup>  
N = 70

Or



Rituximab  
375 mg/m<sup>2</sup>  
N = 69

Glucocorticoids  
tapered till  
withdrawal

## Results (2 years follow up)

26 %

Primary endpoint  
Recurrence of  
nephrotic syndrome

OR - 1.45  
(95% CI 0.8 to 2.7)

37%



No severe adverse effects in both arms